CN112662604A - Recombinant escherichia coli for synthesizing 3-fucosyllactose and construction method thereof - Google Patents
Recombinant escherichia coli for synthesizing 3-fucosyllactose and construction method thereof Download PDFInfo
- Publication number
- CN112662604A CN112662604A CN202011604645.8A CN202011604645A CN112662604A CN 112662604 A CN112662604 A CN 112662604A CN 202011604645 A CN202011604645 A CN 202011604645A CN 112662604 A CN112662604 A CN 112662604A
- Authority
- CN
- China
- Prior art keywords
- gene
- escherichia coli
- recombinant
- seq
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000588724 Escherichia coli Species 0.000 title claims abstract description 59
- AUNPEJDACLEKSC-ZAYDSPBTSA-N 3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O AUNPEJDACLEKSC-ZAYDSPBTSA-N 0.000 title claims abstract description 50
- WJPIUUDKRHCAEL-UHFFFAOYSA-N 3FL Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(O)C1O WJPIUUDKRHCAEL-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 26
- 238000010276 construction Methods 0.000 title claims abstract description 16
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 18
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 17
- QGWNDRXFNXRZMB-UUOKFMHZSA-N GDP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 claims abstract description 14
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 claims abstract description 14
- 108090000790 Enzymes Proteins 0.000 claims abstract description 13
- 108010019236 Fucosyltransferases Proteins 0.000 claims abstract description 11
- 239000011435 rock Substances 0.000 claims abstract description 11
- 108010060845 lactose permease Proteins 0.000 claims abstract description 10
- 108010005774 beta-Galactosidase Proteins 0.000 claims abstract description 8
- 230000014509 gene expression Effects 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 239000013612 plasmid Substances 0.000 claims description 35
- 101150066555 lacZ gene Proteins 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 26
- 125000003729 nucleotide group Chemical group 0.000 claims description 26
- 238000011144 upstream manufacturing Methods 0.000 claims description 21
- 238000010354 CRISPR gene editing Methods 0.000 claims description 18
- 238000005516 engineering process Methods 0.000 claims description 17
- 101100075927 Aspergillus aculeatus mndA gene Proteins 0.000 claims description 16
- 101150088678 manB gene Proteins 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 14
- 101100156625 Escherichia coli (strain K12) wcaJ gene Proteins 0.000 claims description 13
- 101150018163 wcaJ gene Proteins 0.000 claims description 12
- LQEBEXMHBLQMDB-QIXZNPMTSA-N GDP-L-fucose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)OC1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1 LQEBEXMHBLQMDB-QIXZNPMTSA-N 0.000 claims description 11
- 238000003209 gene knockout Methods 0.000 claims description 11
- 101100022282 Escherichia coli O157:H7 manC2 gene Proteins 0.000 claims description 10
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 10
- 101150032120 manC gene Proteins 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 claims description 9
- 108020005004 Guide RNA Proteins 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 9
- 238000010362 genome editing Methods 0.000 claims description 9
- 238000012408 PCR amplification Methods 0.000 claims description 8
- 230000037361 pathway Effects 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 238000012795 verification Methods 0.000 claims description 7
- 108091033409 CRISPR Proteins 0.000 claims description 6
- GBXZONVFWYCRPT-KVTDHHQDSA-N [(2s,3s,4r,5r)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl] dihydrogen phosphate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](C=O)OP(O)(O)=O GBXZONVFWYCRPT-KVTDHHQDSA-N 0.000 claims description 6
- 230000037353 metabolic pathway Effects 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 238000012163 sequencing technique Methods 0.000 claims description 6
- 230000001131 transforming effect Effects 0.000 claims description 6
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 5
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 5
- 229940029575 guanosine Drugs 0.000 claims description 5
- 230000001320 lysogenic effect Effects 0.000 claims description 5
- RSLLXTJELTWVHR-FNORWQNLSA-N (3e)-undeca-1,3-diene Chemical compound CCCCCCC\C=C\C=C RSLLXTJELTWVHR-FNORWQNLSA-N 0.000 claims description 4
- 241000702462 Akkermansia muciniphila Species 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 4
- 244000228088 Cola acuminata Species 0.000 claims description 4
- 235000010205 Cola acuminata Nutrition 0.000 claims description 4
- 235000015438 Cola nitida Nutrition 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 108091000080 Phosphotransferase Proteins 0.000 claims description 4
- 108090000992 Transferases Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 102000006471 Fucosyltransferases Human genes 0.000 claims description 3
- 108090000364 Ligases Proteins 0.000 claims description 3
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 238000002474 experimental method Methods 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- HXXFSFRBOHSIMQ-RWOPYEJCSA-L alpha-D-mannose 1-phosphate(2-) Chemical compound OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-RWOPYEJCSA-L 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract description 11
- 239000008101 lactose Substances 0.000 abstract description 11
- 108020004705 Codon Proteins 0.000 abstract description 2
- 230000007062 hydrolysis Effects 0.000 abstract description 2
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 2
- 230000003834 intracellular effect Effects 0.000 abstract description 2
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 abstract 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 abstract 1
- 229960003324 clavulanic acid Drugs 0.000 abstract 1
- 238000005457 optimization Methods 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 23
- 239000000047 product Substances 0.000 description 17
- 238000000855 fermentation Methods 0.000 description 15
- 230000004151 fermentation Effects 0.000 description 15
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 12
- 101100168102 Yersinia pseudotuberculosis colC gene Proteins 0.000 description 8
- 101150041441 fcl gene Proteins 0.000 description 8
- 101150106565 gmd gene Proteins 0.000 description 8
- 235000020256 human milk Nutrition 0.000 description 8
- 210000004251 human milk Anatomy 0.000 description 8
- 230000003321 amplification Effects 0.000 description 7
- 101150001899 lacY gene Proteins 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 229930027917 kanamycin Natural products 0.000 description 6
- 229960000318 kanamycin Drugs 0.000 description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
- 229930182823 kanamycin A Natural products 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- 229960005322 streptomycin Drugs 0.000 description 6
- 241000660147 Escherichia coli str. K-12 substr. MG1655 Species 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 102000012410 DNA Ligases Human genes 0.000 description 4
- 108010061982 DNA Ligases Proteins 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 238000011031 large-scale manufacturing process Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 108010089934 carbohydrase Proteins 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003208 gene overexpression Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012269 metabolic engineering Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention provides a recombinant escherichia coli for synthesizing 3-fucosyllactose and a construction method thereof, wherein the recombinant escherichia coli is obtained by knocking out beta-galactosidase genes in the genome of the escherichia coli, synthesizing key enzyme genes of clavulanic acid from guanosine diphosphate rock sugar, strengthening and expressing key enzyme genes of a lactose permease gene and guanosine diphosphate rock sugar de-novo synthesis way, and expressing exogenous fucosyltransferase genes. The scheme of the invention can reduce lactose hydrolysis and improve the speed of transferring exogenous lactose into cells, thereby effectively improving the concentration of lactose in the cells; meanwhile, the consumption of the guanosine diphosphate rock sugar is reduced, and the intracellular guanosine diphosphate rock sugar concentration is effectively improved; the expression of exogenous fucosyltransferase gene is improved through codon optimization, and the synthesis of 3-fucosyllactose is effectively promoted.
Description
Technical Field
The invention relates to the technical field of genetic engineering, in particular to recombinant escherichia coli for synthesizing 3-fucosyllactose and a construction method thereof.
Background
Breast milk is a complex mixture containing water, fat, protein, minerals, vitamins, polysaccharides, monosaccharides, disaccharides (lactose), oligosaccharides. Lactose is the main solid component of breast milk (-6.8% of total solids) and is widely present in animal milk. However, breast milk oligosaccharides with a more complex structure (-1% of total solids) are unique to humans. Currently, there are about 200 breast milk oligosaccharides with a well-established structure, and the degree of polymerization varies from 3 to 32. Structural features of breast milk oligosaccharides include lacto-N-acetylglucosamine backbone, straight chain β - (1,3/4) -glycosidic linkages, branched chain β - (1,6) -glycosidic linkages, lactose at the reducing end of the sugar chain and L-fucose or sialic acid at the non-reducing end.
3-fucosyllactose is a commonly occurring and abundant oligosaccharide in breast milk of lactating mothers. The proportion of 3-fucosyllactose in the total amount of oligosaccharide in breast milk can be up to 5%. Therefore, the study of 3-fucosyllactose is more thorough, and 3-fucosyllactose is found to have various beneficial functions. For example, 3-fucosyllactose specifically inhibits the binding of pathogenic e.coli, norovirus, to the corresponding host receptor to avoid infection. The 3-fucosyllactose can inhibit the interaction of Pseudomonas aeruginosa with local epithelial cells, thereby preventing infection of gastrointestinal tract, urethra and respiratory system by Pseudomonas aeruginosa. The 3-fucosyllactose can also specifically proliferate intestinal specific beneficial bacteria so as to regulate the structure and function of intestinal flora. In addition, 3-fucosyllactose enhances intestinal mucus barrier function by up-regulating the expression of genes involved in intestinal goblet cell secretion.
The 3-fucosyllactose is beneficial to health, and related test data show that the 3-fucosyllactose meets the requirements of food safety regulations and is expected to be used as a functional food raw material of infant formula foods and medical nutritional products. However, industrial production of 3-fucosyllactose is not easy. Early, 3-fucosyllactose was chromatographically isolated from donated breast milk and could not be produced on a large scale due to limited material sources. 3-fucosyllactose can be directly chemically synthesized, however, is limited by the chemical nature of the protecting group, cannot be scaled up, and chemical synthesis requires the use of toxic reagents and is less suitable for large-scale food production. Fucosyltransferase can catalyze the synthesis of 3-fucosyllactose in vitro, however, the donor substrate, guanosine diphosphate fucose, is very expensive. Therefore, the enzymatic synthesis of 3-fucosyllactose is not suitable for industrial production of several hundred tons per year. Microbial fermentation is currently the only technical route suitable for large-scale production. The technological progress of metabolic engineering, fermentation engineering, purification process and the like makes the large-scale production of the 3-fucosyllactose gradually become practical. During the fermentation process, the donor substrate molecule, guanosine diphosphate fucose, is synthesized de novo by the microorganism itself, while the acceptor substrate molecule, lactose, is generally added externally.
Therefore, the technical personnel in the field need to solve the problems by constructing the recombinant escherichia coli for synthesizing the 3-fucosyllactose, effectively promoting the fermentation and synthesis of the 3-fucosyllactose and laying a solid foundation for future large-scale production.
Disclosure of Invention
In view of the above, the technical problem to be solved by the present invention is to provide a recombinant escherichia coli for synthesizing 3-fucosyllactose and a construction method thereof, which overcome the problems of long test period, low success rate and the like of homologous recombination technology, optimize the expression of exogenous fucosyltransferase gene, and effectively promote the synthesis of 3-fucosyllactose, thereby realizing the high-efficiency fermentation synthesis of 3-fucosyllactose.
In order to solve the above technical problems, in one aspect, the present invention provides a recombinant escherichia coli for synthesizing 3-fucosyllactose, wherein the recombinant escherichia coli is obtained by knocking out a beta-galactosidase gene from a genome of an original strain of escherichia coli, synthesizing a key enzyme gene of kola acid from guanosine diphosphate fucose, intensively expressing a lactose permease gene and a key enzyme gene of a guanosine diphosphate fucose de-novo synthesis pathway, and expressing an exogenous fucosyltransferase gene.
Preferably, the beta-galactosidase gene is knocked out by using a CRISPR gene editing technology, and the key enzyme gene for synthesizing the kola acid from the guanosine diphosphate fucose is knocked out by using the CRISPR gene editing technology, namely, the undecadiene phosphate glucose phosphotransferase gene wcaJ is knocked out.
Preferably, when the gene wcaJ of undecadiene phosphate glucose phosphotransferase gene wcaJ is knocked out by using the CRISPR gene editing technology, the nucleotide sequence of the target sequence of gRNA1 of the knocked-out gene wcaJ is shown as SEQ ID No.1, the nucleotide sequence of the target sequence of gRNA2 of the knocked-out gene wcaJ is shown as SEQ ID No.2, the nucleotide sequence of an upstream primer identified by PCR is shown as SEQ ID No.3, and the nucleotide sequence of a downstream primer identified by PCR is shown as SEQ ID No. 4.
Preferably, when the CRISPR gene editing technology is used for knocking out the beta-galactosidase gene lacZ, the nucleotide sequence of the target sequence of the gRNA1 of the knocked-out gene lacZ is shown as SEQ ID No.5, the nucleotide sequence of the target sequence of the gRNA2 of the knocked-out gene lacZ is shown as SEQ ID No.6, the nucleotide sequence of the upstream primer identified by PCR is shown as SEQ ID No.7, and the nucleotide sequence of the downstream primer identified by PCR is shown as SEQ ID No. 8.
Preferably, the enhanced expression of the lactose permease gene and the key enzyme gene of the guanosine diphosphate rock sugar de novo synthesis pathway refers to the fact that a T7lac promoter is knocked in the upstream of a phosphomannose mutase gene manB of the guanosine diphosphate rock sugar de novo synthesis pathway by using a CRISPR gene editing technology.
Preferably, when a T7lac promoter is knocked in from the upstream of a phosphomannose mutase gene manB in a guanosine diphosphate fucose de novo synthesis pathway by using a CRISPR gene editing technology, the nucleotide sequence of a knocked-in fragment is shown as SEQ ID NO.9, the nucleotide sequence of a knocked-in position upstream gene is shown as SEQ ID NO.10, the nucleotide sequence of a knocked-in position downstream gene is shown as SEQ ID NO.11, the nucleotide sequence of an upstream primer identified by PCR is shown as SEQ ID NO.12, and the nucleotide sequence of a downstream primer identified by PCR is shown as SEQ ID NO. 13.
Preferably, the recombinant escherichia coli carries a plurality of recombinant plasmids for inducing high expression of proteins, wherein the recombinant plasmids respectively comprise genes manB, mannose-1-phosphate guanosine transferase genes manC, guanosine diphosphate mannose-4, 6-dehydratase genes gmd, guanosine diphosphate-L-fucose synthetase genes fcl, lactose permease genes lacY and exogenous fucosyltransferase genes.
Preferably, the exogenous fucosyltransferase cafF gene is derived from Ackermansia muciniphila, and the codon-optimized cafF gene sequence is shown in SEQ ID No. 14.
Preferably, the original strain is E.coli, preferably E.coli BL21(DE 3).
In the specific implementation process, the invention provides a recombinant escherichia coli for synthesizing 3-fucosyllactose, and the undecadiene phosphate glucose phosphotransferase gene wcaJ and the beta-galactosidase gene lacZ of the original strain genome are knocked out by adopting a CRISPR gene editing technology. At the same time, the T7lac promoter was knocked in upstream of the phosphomannose mutase gene manB of the de novo synthesis pathway of guanosine diphosphate rock sugar. And simultaneously overexpresses phosphomannose mutase gene manB, mannose-1-phosphoguanosine transferase gene manC, guanosine diphosphate mannose-4, 6-dehydratase gene gmd, guanosine diphosphate-L-fucose synthetase gene fcl, lactose permease gene lacY and codon optimized alpha-1, 3-fucose transferase gene cafF.
The gene wcaJ, gene accession number GI: 8182600; gene lacZ, gene accession number GI: 8181469; gene manB, gene accession number GI: 946574; gene manC, gene accession number GI: 946580; gene gmd, gene accession number GI: 946562; gene fcl, gene accession number GI 946563; gene lacY, gene accession number GI: 949083; gene cafF, gene accession number GI: 187425317. The gene overexpression refers to the induction high expression of the protease molecules corresponding to each gene by adopting a recombinant plasmid expression vector.
On the other hand, the invention also provides a construction method of the recombinant escherichia coli for synthesizing the 3-fucosyllactose, which comprises the following steps:
1) respectively preparing recombinant plasmids containing gene manB, gene manC, gene gmd, gene fcl, lactose permease gene lacY and codon-optimized gene cafF to obtain plasmids for constructing metabolic pathways;
2) the detection shows that the growth state of the original strain of escherichia coli BL21(DE3) is normal, the detection of the knock-in positions of target genes wcaJ and lacZ and a T7lac promoter and upstream and downstream sequences shows that the size of a PCR amplification band accords with the expectation, and the sequencing result is consistent with the NCBI sequence;
3) designing and preparing gRNA according to the insertion position of a target gene sequence and the sequence characteristics around the target gene sequence, cloning the gRNA and the Donor sequence to a gene editing vector Donor plasmid, and ensuring that the gRNA and the Donor sequence in the constructed vector are consistent with the target sequence through sequencing verification;
4) preparing escherichia coli BL21(DE3) electrotransformation competence, transforming Cas9 plasmid into BL21(DE3) competence, selecting spots to prepare BL21(DE3) -Cas9 electrotransformation competence, transforming Donor plasmid into BL21(DE3) -Cas9 electrotransformation competence, adding arabinose for induction, coating a plate, and carrying out gene editing strain screening experiment;
5) PCR amplification verifies that the edited BL21(DE3) is monoclonal, the size of a band successfully knocked out by the wcaJ gene is 771bp, and the size of a band successfully knocked out is 1049 bp; the size of a successful band of the lacZ gene knockout is 687bp, and the size of a successful band of the lacZ gene knockout is 983 bp; the size of a band of the T7lac promoter which is knocked in successfully is 1076bp, and no band exists when the promoter is not knocked in successfully; electrophorograms show that monoclonals with the wcaJ gene and the lacZ gene knocked out simultaneously and the T7lac promoter knocked in are successfully screened;
6) carrying out lysogenic treatment on the escherichia coli edited by the CRISPR in the step 5), and then converting the metabolic pathway construction plasmid obtained in the step 1) into lysogenic bacteria to obtain the recombinant escherichia coli capable of synthesizing 3-fucosyllactose.
The recombinant escherichia coli is fermented and synthesized into the 3-fucosyllactose, and the culture medium and the fermentation method are as follows:
LB medium (1L) tryptone, 10 g; yeast extract, 5 g; sodium chloride, 5 g. Preparing a solid culture medium, and then adding 15g of agar powder.
The recombinant E.coli of the present invention was cultured in 2mL of LB medium (kanamycin 50. mu.g/mL, streptomycin 50. mu.g/mL) at 37 ℃ and shaking table rotation speed 220rpm overnight for about 15 hours. Transferring 1mL of overnight-cultured seed solution into 50mL of LB medium (kanamycin 50. mu.g/mL, streptomycin 50. mu.g/mL, glucose added to a final concentration of 20 g/L), culturing at 30 ℃ and shaking table rotation speed of 250rpm for about 8h (bacterial solution OD)600About 0.8). Lactose was added to a final concentration of 12g/L and IPTG was added at 0.3mM, and the fermentation was continued for 48h at 25 ℃ and a shaker speed of 250 rpm.
Compared with the prior art, the invention discloses a recombinant escherichia coli for synthesizing 3-fucosyllactose and a construction method thereof, and the construction method has the positive effects that:
(1) the recombinant escherichia coli has a metabolic pathway for fermenting and synthesizing 3-fucosyllactose, simultaneously overcomes the problems of long test period, low success rate and the like of a homologous recombination technology, and obtains an efficient genome editing scheme; except for synthesizing 3-fucosyllactose, other characteristics of the original strain are not changed, and fermentation is not influenced; the adopted plasmid is a common escherichia coli plasmid, and the growth and metabolism of bacteria are not influenced.
(2) By improving the concentration of intracellular lactose and guanosine diphosphate fucose and optimizing the expression of exogenous fucosyltransferase gene, the synthesis of 3-fucosyllactose is effectively promoted; the recombinant escherichia coli has clear construction thought, obvious actual effect and good application prospect.
(3) The recombinant escherichia coli takes glucose as a carbon source to ferment and synthesize the 3-fucosyllactose, the cost is lower, the economic feasibility is higher, and the 3-fucosyllactose with the concentration of 1.0-1.5 g/L can be obtained after fermentation for 48 hours.
(4) The recombinant escherichia coli is very stable in the amplification process and has great industrial application potential.
Drawings
FIG. 1 is an electrophoretogram of PCR-verified products of the wcaJ gene knockout;
(wcaJ-WT is an amplification product of wcaJ gene; wcaJ-Edit is an amplification product of wcaJ gene after knockout)
FIG. 2 is an electrophoretogram of PCR-verified products of lacZ gene knock-out;
(lacZ-WT is an amplification product of lacZ gene; lacZ-Edit is an amplification product of lacZ gene after knockout)
FIG. 3 is an electrophoretogram of PCR-verified products of knock-in of the T7lac promoter;
(7Lac-WT is an amplification product of a non-knock-in T7 Lac; 7Lac-Edit is an amplification product of a successful knock-in T7 Lac)
FIG. 4 is a chromatogram of an ion chromatography detection fermentation broth, wherein the chromatographic peak at 11.159 minutes is 3-fucosyllactose.
Detailed Description
The invention is described below by means of specific embodiments. Unless otherwise specified, the technical means used in the present invention are well known to those skilled in the art. In addition, the embodiments should be considered illustrative, and not restrictive, of the scope of the invention, which is defined solely by the claims. It will be apparent to those skilled in the art that various changes or modifications in the components and amounts of the materials used in these embodiments can be made without departing from the spirit and scope of the invention. The raw materials and reagents used in the present invention are commercially available. The materials, reagents, apparatus and methods used in the following examples are all conventional in the art and are commercially available.
Example 1
Obtaining of genes:
in this example, a gene manB derived from Escherichia coli MG1655 (Gene accession number GI:946574), a gene manC (Gene accession number GI:946580), a gene gmd (Gene accession number GI:946562), a gene fcl (Gene accession number GI:946563), a gene lacY (Gene accession number GI:949083) and a gene cafF derived from Ackermanella viscocata ATCC BAA-835 (Gene accession number GI: 187425317) were obtained.
In the embodiment, Escherichia coli genes manB, manC, gmd, fcl and lacY are successfully obtained by extracting the genomic DNA of Escherichia coli MG 1655; the gene cafF derived from Ackermansia muciniphila ATCC BAA-835 was successfully obtained by artificially synthesizing a codon-optimized gene and cloning it into an Escherichia coli plasmid. The successful acquisition of the gene lays a foundation for the construction of recombinant plasmids.
Example 2
Preparation of recombinant plasmid
The gene manC and gene manB derived from Escherichia coli MG1655 obtained in example 1 were subjected to PCR amplification using designed primers (the sequence of the upstream primer is shown in SEQ ID NO.15 and the sequence of the downstream primer is shown in SEQ ID NO. 16), the amplified fragments were subjected to gel-cutting purification and double-digested with restriction enzymes NcoI and HindIII, the digested fragments were ligated with plasmid pCOLADuet-1 which was also double-digested with NcoI and HindIII, and the vector: the target fragments were mixed at a molar ratio of 1:3, and after addition of T4 DNA ligase, they were enzymatically ligated at 22 ℃ for 5 hours, and the ligation products were transformed into E.coli DH 5. alpha. competent cells and screened on kanamycin plates to obtain recombinant plasmid pCOLA-CB. The gene gmd and the gene fcl derived from Escherichia coli MG1655 obtained in example 1 were subjected to PCR amplification using designed primers (the sequence of the upstream primer is shown in SEQ ID NO.17 and the sequence of the downstream primer is shown in SEQ ID NO. 18), the amplified fragments were subjected to gel cutting purification and double-digested with NdeI and XhoI, the digested fragments were ligated to plasmid pCOLA-CB which was also double-digested with NdeI and XhoI, and the vector: the target fragments are mixed according to the molar ratio of 1:3, T4 DNA ligase is added, then enzyme linkage is carried out for 5 hours at 22 ℃, the ligation product is transformed into escherichia coli DH5 alpha competent cells, and screening is carried out on a kanamycin plate, so as to obtain the recombinant plasmid pCOLA-CBGF.
The gene lacY derived from escherichia coli MG1655 obtained in example 1 was PCR-amplified using designed primers (the sequence of the upstream primer is shown in SEQ ID No.19 and the sequence of the downstream primer is shown in SEQ ID No. 20), the amplified fragment was gel-cut and purified, and double-cut with NdeI and XhoI, and the cut fragment was ligated to plasmid pCDFDuet-1, which was also double-cut with NdeI and XhoI, to vector: the target fragments are mixed according to the molar ratio of 1:3, T4 DNA ligase is added, then enzyme linkage is carried out for 5h at 22 ℃, the ligation product is transformed into escherichia coli DH5 alpha competent cells, and screening is carried out on a streptomycin plate, so as to obtain the recombinant plasmid pCDF-lacY. The gene cafF derived from akkermansia muciniphila obtained in example 1 was amplified by PCR using designed primers (the sequence of the upstream primer is shown in SEQ ID No.21 and the sequence of the downstream primer is shown in SEQ ID No. 22), the amplified fragment was purified by gel cutting and double-digested with NcoI and BamHI, the digested fragment was ligated with the plasmid pCDF-lacY, which was also double-digested with NcoI and BamHI, and the vector: the target fragments are mixed according to the molar ratio of 1:3, T4 DNA ligase is added, then enzyme linkage is carried out for 5h at 22 ℃, the ligation product is transformed into escherichia coli DH5 alpha competent cells, and screening is carried out on a streptomycin plate, so as to obtain the recombinant plasmid pCDF-lacY-cafF.
In this example, the recombinant plasmids pCOLA-CBGF and pCDF-lacY-cafF were successfully prepared, which laid the foundation for the construction of the metabolic pathway related to the 3-fucosyllactose of E.coli.
Example 3
Gene editing
In this example, wcaJ and lacZ gene knockout and T7lac promoter knock-in were achieved using CRISPR gene editing technology. The procedure of gene editing is described in detail below.
1) The detection shows that the growth state of the original strain of escherichia coli BL21(DE3) is normal, the detection of the knock-in positions of target genes wcaJ and lacZ and a T7lac promoter and upstream and downstream sequences shows that the size of a PCR amplification band accords with the expectation, and the sequencing result is consistent with the NCBI sequence;
2) designing and preparing gRNA according to the insertion position of a target gene sequence and the sequence characteristics around the target gene sequence, cloning the gRNA and the Donor sequence to a gene editing vector Donor plasmid, and ensuring that the gRNA and the Donor sequence in the constructed vector are consistent with the target sequence through sequencing verification;
3) preparing escherichia coli BL21(DE3) electrotransformation competence, transforming Cas9 plasmid into BL21(DE3) competence, selecting spots to prepare BL21(DE3) -Cas9 electrotransformation competence, transforming Donor plasmid into BL21(DE3) -Cas9 electrotransformation competence, adding arabinose for induction, coating a plate, and carrying out gene editing strain screening experiment;
5) PCR amplification verifies that the edited BL21(DE3) is monoclonal, the size of a band successfully knocked out by the wcaJ gene is 771bp, and the size of a band successfully knocked out is 1049 bp; the size of a successful band of the lacZ gene knockout is 687bp, and the size of a successful band of the lacZ gene knockout is 983 bp; the size of a band of the T7lac promoter which is knocked in successfully is 1076bp, and no band exists when the promoter is not knocked in successfully; electrophorograms show that monoclonals with both the wcaJ gene and the lacZ gene knocked out and the T7lac promoter knocked in were successfully screened.
In this example, the wcaJ gene of escherichia coli BL21(DE3) was knocked out by CRISPR gene editing technology (fig. 1 is an electrophoretogram of PCR-verified products of wcaJ gene knock-out), reducing the consumption of guanosine diphosphate fucose; realizing the knockout of lacZ gene of Escherichia coli BL21(DE3) (FIG. 2 is an electrophoretogram of PCR verification product of lacZ gene knockout), and reducing the hydrolysis of lactose in cells; realizes the knock-in of the T7lac promoter at the upstream of the gene manB of the genome of the escherichia coli (figure 3 is an electrophoresis chart of a PCR verification product of the knock-in of the T7lac promoter), promotes the genes manB, manC, gmd and fcl to express corresponding carbohydrases, and improves the content of guanosine diphosphate fucose in cells. The successful implementation of the three aspects can effectively promote the escherichia coli to synthesize the 3-fucosyllactose.
Example 4
Construction of recombinant Escherichia coli for synthesizing 3-fucosyllactose
Coli edited by CRISPR in example 3 was subjected to lysogenic treatment, and the metabolic pathway-constructing plasmid obtained in example 2 was transformed into lysogens to obtain recombinant escherichia coli capable of synthesizing 3-fucosyllactose.
In the embodiment, the recombinant escherichia coli for synthesizing the 3-fucosyllactose is successfully obtained, and a foundation is laid for further fermentation verification.
Example 5
Verification of 3-fucosyllactose synthesized by recombinant escherichia coli
The strain was inoculated in 2mL of LB medium (kanamycin 50. mu.g/mL, streptomycin 50. mu.g/mL) at 37 ℃ and incubated overnight at 220rpm on a shaker for about 15 hours. Transferring 1mL of overnight-cultured seed solution into 50mL of LB medium (kanamycin 50. mu.g/mL, streptomycin 50. mu.g/mL, glucose added to a final concentration of 20 g/L), culturing at 30 ℃ and shaking table rotation speed of 250rpm for about 8h (bacterial solution OD)600About 0.8). Lactose was added to a final concentration of 12g/L and IPTG was added at 0.3mM, and the fermentation was continued for 48h at 25 ℃ and a shaker speed of 250 rpm. Centrifuging the fermentation liquid at 8000rpm for 10min, collecting supernatant, decocting the supernatant at 100 deg.C for 10min, centrifuging again, mixing 0.5mL supernatant with 0.5mL purified water, filtering the sample with 0.22 μm filter membrane, and detecting by high performance liquid chromatography (FIG. 4 is ion chromatography detection fermentation liquid chromatogram, wherein the chromatographic peak of 11.159 min is 3-fucosyllactose).
In the embodiment, the high performance liquid chromatography detection of the shake flask fermentation liquid shows that the recombinant escherichia coli successfully synthesizes the 3-fucosyllactose, and lays a foundation for further pilot scale-up and industrial production.
Although the present invention has been described in detail with reference to the above embodiments, it will be apparent to one skilled in the art that modifications may be made to the embodiments described in the foregoing embodiments, or equivalents may be substituted for some of the features thereof. And such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions.
Sequence listing
<110> Quantum Gaokou (Guangdong) Biometrics Ltd
<120> recombinant escherichia coli for synthesizing 3-fucosyllactose and construction method thereof
<160> 22
<170> SIPOSequenceListing 1.0
<210> 1
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
ttgccctgct gctacaaaac tgg 23
<210> 2
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
gccgtggtta gggtttgaag tgg 23
<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
gtgcgcctga atgtggaatc 20
<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
gagctcagtt tcaccgccag 20
<210> 5
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
atggcgaatg gcgctttgcc tgg 23
<210> 6
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
ttaactcggc gtttcatctg tgg 23
<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
ccaatacgca aaccgcctct 20
<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
ttacccgtag gtagtcacgc 20
<210> 9
<211> 120
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
gaggatcgag atcgatctcg atcccgcgaa attaatacga ctcactatag gggaattgtg 60
agcggataac aattcccctc tagaaataat tttgtttaac tttaagaagg agatatacat 120
<210> 10
<211> 575
<212> DNA
<213> Escherichia coli (Escherichia coli)
<400> 10
atgcaggatt taagtggatt ctcggtgccg aaagggttcc ggggtggcaa cgctattaaa 60
gtgcaattgt ggtgggcagt acaggcaaca ttatttgcct ggtcgccaca agtattgtat 120
cgctggcggg catttttatt acgtttattc ggcgcaaaaa tagggaaaaa cgtagttatt 180
cgtccgtcag taaaaattac ctatccgtgg aaattaacct taggtgatta cgcgtgggtc 240
ggcgatgacg tcaatttata taccctcggt gaaataacca ttggcgcaca ttcggtgata 300
tcgcaaaaaa gttatttatg caccggtagc cacgaccatg caagtcaaca tttcaccatt 360
aatgctacgc ctattgtgat tggcgagaaa tgctggctgg caaccgatgt ttttgttgcc 420
cctggcgtca cgattggcga cggcaccgtc gtgggtgcac gaagcagtgt ttttaaaacg 480
cttccggcaa atgtggtttg ccgggggaat cccgcagtgg tgatacgcga acgcgttgaa 540
actgaataaa ttcaaaaaat acagaggaat aagac 575
<210> 11
<211> 1122
<212> DNA
<213> Escherichia coli (Escherichia coli)
<400> 11
atgtcaaaag tcgctctcat caccggtgta accggacaag acggttctta cctggcagag 60
tttctgctgg aaaaaggtta cgaggtgcat ggtattaagc gtcgtgcatc gtcattcaac 120
accgagcgcg tggatcacat ttatcaggat ccgcacacct gcaacccgaa attccatctg 180
cattatggcg acctgagtga tacctccaac ctgacacgca ttttgcgtga agtgcagccg 240
gatgaagtgt ataacctggg cgcaatgagc cacgttgcgg tctcttttga gtcaccggaa 300
tataccgcag acgttgatgc gatgggtacg ctgcgcctgc tcgaggcgat ccgcttcctc 360
ggtctggaaa agaaaacccg tttttatcag gcttccacct ctgaactgta cggtctggtg 420
caggaaattc cgcagaaaga aactacgccg ttctacccgc gatctccgta tgcggtcgcc 480
aaactgtacg cctactggat caccgttaac taccgcgaat cctacggcat gtacgcctgt 540
aacggtattc tcttcaacca tgaatccccg cgccgcggtg aaaccttcgt tacccgcaaa 600
atcacccgcg caatcgccaa tatcgcccag gggctggagt cgtgcctgta cctcggcaat 660
atggattccc tgcgtgactg gggccatgcc aaagactacg taaaaatgca gtggatgatg 720
ctgcaacagg aacagccgga agatttcgtt attgctaccg gcgttcagta ctccgtacgt 780
cagttcgtgg aaatggcggc agcacagttg ggcatcaaac tgcgctttga aggcacgggt 840
gttgaagaga agggcattgt ggtttccgtc accgggcatg acgcgccggg cgttaaaccg 900
ggtgatgtga ttatcgccgt tgacccgcgt tacttccgtc cggcagaagt tgaaacgctg 960
ctcggcgacc cgaccaaagc gcacgaaaaa ctgggctgga aaccggaaat caccctcaga 1020
gagatggtgt ctgaaatggt ggctaatgac ctcgaagcgg cgaaaaaaca ctctctgctg 1080
aaatctcacg gctacgacgt ggcgatcgcg ctggagtcat aa 1122
<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
gaggatcgag atcgatctcg 20
<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 13
gtttcaactt ctgccggacg 20
<210> 14
<211> 999
<212> DNA
<213> Akkermansia muciniphila (akkermansia muciniphila)
<400> 14
atgaagaccc tgaaaattag ctttctgcag agcaccccgg actttggtcg tgaaggcatg 60
ctgcagctgc tgaaaagtcg gtaccacgtt gtggaagacg acagcgattt tgattacctg 120
gtggcaaccc cgtggttcta tgttaaccgg gaagcttttt atgatttttt agaacgggcc 180
ccgggtcata ttaccgttat gtatggttgt catgaagcaa ttgcaccgga ttttatgtta 240
tttgattact atatcggtct tgacacagtg ccgggtagcg atcgtaccgt gaaactgcct 300
tatttacgtc atcatctgga agaagttcac ggcggaaagg aaggtttaga tgcgcatgcg 360
ctgctggcaa gcaaaaccgg attttgtaac tttatatacg caaaccgtaa gtctcatccg 420
aatcgtgatg caatgtttca taaactgagc gcatttcgtt ttgttaatag tctgggtccg 480
catttaaata ataccccggg tgatggccat cgcgccgaag attggtatgc cagcagcatc 540
cgtatgaaaa agccgtacaa atttagcatt gcctttgaga atgcatggta tccgggttac 600
accagcgaaa aaattgttac cagcatgctg gcaggtacca ttccgattta ttggggtaat 660
ccggatatta gccgtgaatt taatagcgca agctttatta attgtcatga ttttccgacc 720
ctggatgatg cagcagcata tgttaaaaaa gttgatgaag atgataatct gtggtgtgaa 780
attatgagcc gtccgtggaa aaccccggaa caggaagcac gttttctgga agaaaccgaa 840
cgtgaaaccg caaaactgta taaaattttt gatcagagcc cggaagaagc acgtcgtaaa 900
ggtgatggta cctgggttag ctattatcag cgttttctga aacgtggtca tcgtatgcag 960
ctggcatggc gtcgtctgaa aaatcgtctg cgtcgttaa 999
<210> 15
<211> 31
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 15
cataccatgg cgcagtcgaa actctatcca g 31
<210> 16
<211> 30
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 16
cccaagcttt ggggtaaggg aagatccgac 30
<210> 17
<211> 30
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 17
cgccatatgt caaaagtcgc tctcatcacc 30
<210> 18
<211> 31
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 18
ccgctcgagt tcctgacgta aaaacatcat t 31
<210> 19
<211> 34
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 19
gaaagatctt atgtactatt taaaaaacac aaac 34
<210> 20
<211> 27
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 20
attggtacct taagcgactt cattcac 27
<210> 21
<211> 51
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 21
ctttaataag gagatatacc atgggcatga agaccctgaa aattagcttt c 51
<210> 22
<211> 50
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 22
cgcgccgagc tcgaattcgg atccttaacg acgcagacga tttttcagac 50
Claims (10)
1. A recombinant Escherichia coli for synthesizing 3-fucosyllactose is characterized in that: the recombinant escherichia coli is obtained by knocking out a beta-galactosidase gene from a genome of an original escherichia coli strain, synthesizing a key enzyme gene of kola acid from guanosine diphosphate rock sugar, intensively expressing a key enzyme gene of a lactose permease gene and guanosine diphosphate rock sugar de-novo synthesis way, and expressing an exogenous fucosyltransferase gene.
2. The recombinant E.coli of claim 1, wherein: the beta-galactosidase gene is knocked out by using a CRISPR gene editing technology, and the key enzyme gene for synthesizing the kola acid from the guanosine diphosphate fucose is knocked out by using the CRISPR gene editing technology.
3. The recombinant E.coli of claim 2, wherein: when the CRISPR gene editing technology is utilized to knock out an undecadiene phosphate glucose phosphotransferase gene wcaJ, the nucleotide sequence of the target sequence of gRNA1 of the gene wcaJ is shown as SEQ ID No.1, the nucleotide sequence of the target sequence of gRNA2 of the gene wcaJ is shown as SEQ ID No.2, the nucleotide sequence of an upstream primer identified by PCR is shown as SEQ ID No.3, and the nucleotide sequence of a downstream primer identified by PCR is shown as SEQ ID No. 4.
4. The recombinant E.coli of claim 2, wherein: when the CRISPR gene editing technology is used for knocking out beta-galactosidase gene lacZ, the nucleotide sequence of the target sequence of gRNA1 of the knocked-out gene lacZ is shown as SEQ ID No.5, the nucleotide sequence of the target sequence of gRNA2 of the knocked-out gene lacZ is shown as SEQ ID No.6, the nucleotide sequence of an upstream primer identified by PCR is shown as SEQ ID No.7, and the nucleotide sequence of a downstream primer identified by PCR is shown as SEQ ID No. 8.
5. The recombinant E.coli of claim 1, wherein: the expression-enhanced lactose permease gene and the key enzyme gene of the guanosine diphosphate rock sugar de novo synthesis pathway refer to that a T7lac promoter is knocked in at the upstream of a phosphomannose mutase gene manB of the guanosine diphosphate rock sugar de novo synthesis pathway by using a CRISPR gene editing technology.
6. The recombinant E.coli of claim 5, wherein: when a T7lac promoter is knocked in at the upstream of a phosphomannose mutase gene manB in a guanosine diphosphate fucose de novo synthesis pathway by using a CRISPR gene editing technology, the nucleotide sequence of a knock-in fragment is shown as SEQ ID NO.9, the nucleotide sequence of a knock-in position upstream gene is shown as SEQ ID NO.10, the nucleotide sequence of a knock-in position downstream gene is shown as SEQ ID NO.11, the nucleotide sequence of an upstream primer identified by PCR is shown as SEQ ID NO.12, and the nucleotide sequence of a downstream primer identified by PCR is shown as SEQ ID NO. 13.
7. The recombinant E.coli of claim 1, wherein: the recombinant escherichia coli carries a plurality of recombinant plasmids for inducing high-expression proteins, and the recombinant plasmids respectively comprise genes manB, mannose-1-phosphate guanosine transferase genes manC, guanosine diphosphate mannose-4, 6-dehydratase genes gmd, guanosine diphosphate-L-fucose synthetase genes fcl, lactose permease genes lacY and exogenous fucosyltransferase genes.
8. The recombinant E.coli of claim 7, wherein: the exogenous fucosyltransferase cafF gene is derived from akkermansia muciniphila, and the sequence of the codon-optimized cafF gene is shown in SEQ ID NO. 14.
9. The recombinant E.coli of claim 1, wherein: the original strain is Escherichia coli, preferably Escherichia coli BL21(DE 3).
10. A construction method of recombinant Escherichia coli for synthesizing 3-fucosyllactose is characterized by comprising the following steps:
1) respectively preparing recombinant plasmids containing gene manB, gene manC, gene gmd, gene fcl, lactose permease gene lacY and codon-optimized gene cafF to obtain plasmids for constructing metabolic pathways;
2) the detection shows that the growth state of the original strain of escherichia coli BL21(DE3) is normal, the detection of the knock-in positions of target genes wcaJ and lacZ and a T7lac promoter and upstream and downstream sequences shows that the size of a PCR amplification band accords with the expectation, and the sequencing result is consistent with the NCBI sequence;
3) designing and preparing gRNA according to the insertion position of a target gene sequence and the sequence characteristics around the target gene sequence, cloning the gRNA and the Donor sequence to a gene editing vector Donor plasmid, and ensuring that the gRNA and the Donor sequence in the constructed vector are consistent with the target sequence through sequencing verification;
4) preparing escherichia coli BL21(DE3) electrotransformation competence, transforming Cas9 plasmid into BL21(DE3) competence, selecting spots to prepare BL21(DE3) -Cas9 electrotransformation competence, transforming Donor plasmid into BL21(DE3) -Cas9 electrotransformation competence, adding arabinose for induction, coating a plate, and carrying out gene editing strain screening experiment;
5) PCR amplification verifies that the edited BL21(DE3) is monoclonal, the size of a band successfully knocked out by the wcaJ gene is 771bp, and the size of a band successfully knocked out is 1049 bp; the size of a successful band of the lacZ gene knockout is 687bp, and the size of a successful band of the lacZ gene knockout is 983 bp; the size of a band of the T7lac promoter which is knocked in successfully is 1076bp, and no band exists when the promoter is not knocked in successfully; electrophorograms show that monoclonals with the wcaJ gene and the lacZ gene knocked out simultaneously and the T7lac promoter knocked in are successfully screened;
6) carrying out lysogenic treatment on the escherichia coli edited by the CRISPR in the step 5), and then converting the metabolic pathway construction plasmid obtained in the step 1) into lysogenic bacteria to obtain the recombinant escherichia coli capable of synthesizing 3-fucosyllactose.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011604645.8A CN112662604B (en) | 2020-12-29 | 2020-12-29 | Recombinant escherichia coli for synthesizing 3-fucosyllactose and construction method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011604645.8A CN112662604B (en) | 2020-12-29 | 2020-12-29 | Recombinant escherichia coli for synthesizing 3-fucosyllactose and construction method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112662604A true CN112662604A (en) | 2021-04-16 |
CN112662604B CN112662604B (en) | 2023-10-20 |
Family
ID=75410673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011604645.8A Active CN112662604B (en) | 2020-12-29 | 2020-12-29 | Recombinant escherichia coli for synthesizing 3-fucosyllactose and construction method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112662604B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112625990A (en) * | 2020-12-29 | 2021-04-09 | 量子高科(广东)生物有限公司 | Recombinant escherichia coli for synthesizing 2' -fucosyllactose and construction method thereof |
CN114107152A (en) * | 2021-11-24 | 2022-03-01 | 江南大学 | Construction method and application of high-yield 3-fucosyllactose microorganism |
CN117187206A (en) * | 2023-05-19 | 2023-12-08 | 无锡特殊食品与营养健康研究院有限公司 | Fucosyltransferase from intestinal microorganisms and application thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104293724A (en) * | 2014-09-22 | 2015-01-21 | 上海工业生物技术研发中心 | Genetically engineered bacteria for efficiently producing N-acetylglucosamine |
CN106190937A (en) * | 2016-07-18 | 2016-12-07 | 南开大学 | A kind of method building recombination bacillus coli biosynthesis 2 ' rock algae lactose |
KR20170092159A (en) * | 2016-02-02 | 2017-08-11 | 서울대학교산학협력단 | Method for the mass production of 3-fucosyllactose |
CN109402158A (en) * | 2018-09-14 | 2019-03-01 | 江苏大学 | A kind of recombinant expression plasmid carrier, metabolic engineering bacteria and production method producing fucosyllactose |
US20190309336A1 (en) * | 2016-10-29 | 2019-10-10 | Jennewein Biotechnologie Gmbh | Improved process for the production of fucosylated oligosaccharides |
CN110662842A (en) * | 2017-04-21 | 2020-01-07 | 首尔大学校产学协力团 | Production method of 3' -fucosyllactose using corynebacterium glutamicum |
CN110804577A (en) * | 2019-11-28 | 2020-02-18 | 江南大学 | Escherichia coli engineering strain for producing 2' -fucosyllactose |
WO2020127417A2 (en) * | 2018-12-18 | 2020-06-25 | Inbiose N.V. | PRODUCTION OF 3-FUCOSYLLACTOSE AND LACTOSE CONVERTING α-1,3-FUCOSYLTRANSFERASE ENZYMES |
CN111808790A (en) * | 2020-06-05 | 2020-10-23 | 武汉中科光谷绿色生物技术有限公司 | Escherichia coli and application thereof in synthesis of fucosylated oligosaccharide |
-
2020
- 2020-12-29 CN CN202011604645.8A patent/CN112662604B/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104293724A (en) * | 2014-09-22 | 2015-01-21 | 上海工业生物技术研发中心 | Genetically engineered bacteria for efficiently producing N-acetylglucosamine |
KR20170092159A (en) * | 2016-02-02 | 2017-08-11 | 서울대학교산학협력단 | Method for the mass production of 3-fucosyllactose |
CN106190937A (en) * | 2016-07-18 | 2016-12-07 | 南开大学 | A kind of method building recombination bacillus coli biosynthesis 2 ' rock algae lactose |
US20190309336A1 (en) * | 2016-10-29 | 2019-10-10 | Jennewein Biotechnologie Gmbh | Improved process for the production of fucosylated oligosaccharides |
CN110662842A (en) * | 2017-04-21 | 2020-01-07 | 首尔大学校产学协力团 | Production method of 3' -fucosyllactose using corynebacterium glutamicum |
CN109402158A (en) * | 2018-09-14 | 2019-03-01 | 江苏大学 | A kind of recombinant expression plasmid carrier, metabolic engineering bacteria and production method producing fucosyllactose |
WO2020127417A2 (en) * | 2018-12-18 | 2020-06-25 | Inbiose N.V. | PRODUCTION OF 3-FUCOSYLLACTOSE AND LACTOSE CONVERTING α-1,3-FUCOSYLTRANSFERASE ENZYMES |
CN110804577A (en) * | 2019-11-28 | 2020-02-18 | 江南大学 | Escherichia coli engineering strain for producing 2' -fucosyllactose |
CN111808790A (en) * | 2020-06-05 | 2020-10-23 | 武汉中科光谷绿色生物技术有限公司 | Escherichia coli and application thereof in synthesis of fucosylated oligosaccharide |
Non-Patent Citations (2)
Title |
---|
DI HUANG ET AL.: "Metabolic engineering of Escherichia coli for the production of 2’-fucosyllactose and 3-fucosyllactose through modular pathway enhancement", 《METABOLIC ENGINEERING》 * |
DI HUANG ET AL.: "Metabolic engineering of Escherichia coli for the production of 2’-fucosyllactose and 3-fucosyllactose through modular pathway enhancement", 《METABOLIC ENGINEERING》, vol. 41, 31 December 2017 (2017-12-31), pages 23 - 38, XP055548185, DOI: 10.1016/j.ymben.2017.03.001 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112625990A (en) * | 2020-12-29 | 2021-04-09 | 量子高科(广东)生物有限公司 | Recombinant escherichia coli for synthesizing 2' -fucosyllactose and construction method thereof |
CN112625990B (en) * | 2020-12-29 | 2023-06-16 | 量子高科(广东)生物有限公司 | Recombinant escherichia coli for synthesizing 2' -fucosyllactose and construction method thereof |
CN114107152A (en) * | 2021-11-24 | 2022-03-01 | 江南大学 | Construction method and application of high-yield 3-fucosyllactose microorganism |
CN114107152B (en) * | 2021-11-24 | 2023-07-25 | 江南大学 | Construction method and application of high-yield 3-fucosyllactose microorganism |
CN117187206A (en) * | 2023-05-19 | 2023-12-08 | 无锡特殊食品与营养健康研究院有限公司 | Fucosyltransferase from intestinal microorganisms and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN112662604B (en) | 2023-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111712570B (en) | Engineering strain for producing psicose and derivatives thereof, construction method and application thereof | |
CN112625990B (en) | Recombinant escherichia coli for synthesizing 2' -fucosyllactose and construction method thereof | |
CN106190937B9 (en) | Method for biosynthesizing 2' -fucosyllactose by constructing recombinant escherichia coli | |
CN112662604B (en) | Recombinant escherichia coli for synthesizing 3-fucosyllactose and construction method thereof | |
CN109402158B (en) | Recombinant expression plasmid vector for producing fucosyllactose, metabolic engineering bacteria and production method | |
KR20210099599A (en) | Synthesis of fucosylated oligosaccharide LNFP-V | |
CN112322565B (en) | Method for improving yield of 2' -fucosyllactose in recombinant escherichia coli | |
CN111575220B (en) | Recombinant escherichia coli for synthesizing 2' -fucosyllactose, and construction method and application thereof | |
CN114480240B (en) | Genetic engineering bacterium for producing fucosyllactose and production method thereof | |
CN111548979B (en) | Recombinant escherichia coli for synthesizing lactoyl N-neotetraose and construction method and application thereof | |
EP4276171A1 (en) | Bacillus subtilis genetically engineered bacterium for producing tagatose and method for preparing tagatose | |
CN113136357A (en) | Gene engineering bacterium for producing lactoyl-N-neotetraose and production method | |
CN114774343A (en) | Escherichia coli engineering strain for producing 2' -fucosyllactose and application thereof | |
CN111394292A (en) | Multi-way composite neuraminic acid-producing bacillus subtilis and application thereof | |
WO2023184822A1 (en) | Enzyme co-expression system and use thereof in synthesis of sialic acid | |
CN114874964A (en) | Construction method and application of recombinant escherichia coli for high yield of 2' -fucosyllactose | |
JP2022546825A (en) | Production of sialylated oligosaccharides in Bacillus cells | |
WO2022243312A1 (en) | IDENTIFICATION OF AN α-1,2-FUCOSYLTRANSFERASE FOR THE IN VIVO PRODUCTION OF PURE LNFP-I | |
CN113025548B (en) | Recombinant bacterium for producing 2' -fucosyllactose based on kosakonia sp | |
JP4235262B2 (en) | Production of non-native bacterial exopolysaccharides in recombinant bacterial hosts | |
CN115948314B (en) | Bacillus licheniformis engineering strain for efficiently producing 2' -fucosyllactose | |
CN111394410A (en) | High-catalytic-activity neuraminic acid synthase and application thereof | |
CN115838682A (en) | Bacillus licheniformis engineering strain for efficiently producing 2' -fucosyllactose by utilizing mannan | |
CN113832092B (en) | Genetically engineered bacterium for improving lactoyl-N-fucose yield and production method thereof | |
CN114806991A (en) | Engineering escherichia coli for improving yield of fucosyllactose and production method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |